Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.
EIDX is it a Buy (now)? IGC for Cannabis Alzheimer's, and Marijuana Mania Continues! Aug 27th
We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our product candidate, AG10, is an orally-administered small molecule designed to potently stabilize TTR, a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.
Founded in 2013, Eidos is led by a team of industry veterans who are responsible for developing over 30 molecules through IND applications and more than 10 approved drugs.
Together with patients and physicians, we aim to bring a safe, effective and disease-modifying treatment for ATTR to market as quickly as possible.